Termination of the CRESCENDO trial

The Lancet

Volumn 376, Issue 9757, 2010, Pages 1983-1984

  Roberfroid, Dominique ^a,b   Lachat, Carl ^b   Lucet, Catherine ^c  

^a BELGIAN HEALTH CARE KNOWLEDGE CENTRE KCE   (Belgium)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c International Solidarity in Public Health   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

RIMONABANT;

CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; HUMAN; LETTER; MENTAL DISEASE; OBESITY; PRIORITY JOURNAL; WEIGHT REDUCTION;

EID: 78650097613     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)62254-4     Document Type: Letter

References (5)

1. EJ Topol, M-G Bousser, KAA Fox Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial Lancet 376 2010 517 523
2. R Christensen, PK Kristensen, EM Bartels, H Bliddal, A Astrup Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials Lancet 370 2007 1706 1713
3. C Curioni, C Andre Rimonabant for overweight or obesity Cochrane Database Syst Rev 4 2006 CD006162.
4. FDA Rimonabant briefing document http://www.fda.gov/ohrms/dockets/AC/07/ briefing/2007-4306b1-fda-backgrounder.pdf (accessed Sept 1, 2010).
5. EMEA The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia 2008 European Medicines Agency London http://www.emea.europa.eu/humandocs/PDFs/EPAR/acomplia/53777708en.pdf (accessed Sept 1, 2010).